Sage Therapeutics has priced the oral postpartum depression medicine at USD 15,900 for a full 14-day course of treatment which is developed with Biogen. The pricing of medicine has been announced recently, whereas the drug was approved by the FDA in August.
FDA has approved Zurzuvae for postpartum depression while companies had sought U.S. approval to treat clinical depression and postpartum depression. Postpartum depression is a serious and potentially life-threatening condition in which women experience sadness, guilt, worthlessness—even, in severe cases, thoughts of harming themselves or their child. And, because postpartum depression can disrupt the maternal-infant bond, it can also have consequences for the child’s physical and emotional development
Potential growth catalysts include planned 4Q 2023 launch of ZURZUVAE (zuranolone) and expected data read-outs for SAGE-718 and SAGE-324 in 2024.
Zurzuvae is the first oral pill for the condition that affects one in seven mothers after childbirth. The intravenous PDD treatment Zulresso, also made by Sage, costs USD 34,000 a year.
